TEXT

NCT00066703 📎

Regimen

Experimental
Exemestane 25 mg daily plus OFS (triptorelin) for 5 years.
Control
Tamoxifen 20 mg daily plus OFS (triptorelin) for 5 years.

Population

Premenopausal women with HR+ early breast cancer who started OFS (triptorelin) upfront, concurrently with adjuvant chemotherapy when indicated. Joint analysis with SOFT.

Key finding

TEXT (combined with SOFT) showed exemestane plus OFS reduced invasive recurrences versus tamoxifen plus OFS in premenopausal HR+ early breast cancer. NCCN BINV-K cites SOFT/TEXT as the basis for AI plus OFS in higher-risk premenopausal disease; 15-year updates confirm durable DFS benefit.

Source: PMID 24881463

Timeline

  • Publication: 2014 Jul 10

Guideline citations

  • NCCN BREAST